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A B S T R A C T
A series of new 2-(substitutedphenoxy)-N-[(aryl)methylidene]acetohydrazide analogues (8a-
n) were synthesized in search of potential therapeutics for leishmaniasis. All the compounds
were characterized by infrared (IR), nuclear magnetic resonance (NMR) spectroscopy and
mass spectrometry. The compounds were further evaluated for in vitro antileishmanial ac-
tivity against promastigotes of Leishmania donovani as per the standard protocol reported
elsewhere. 2-(2,4-Dichlorophenoxy)-N′-{[4-(morpholin-4-yl)phenyl]methylidene}acetohydrazide
(8k) showed the most promising antileishmanial activity with IC50 of 48.10 μM, free from
cytotoxicity (>153.08 μM).
© 2016 Beni-Suef University. Production and hosting by Elsevier B.V. This is an open







Leishmaniasis is a neglected infectious disease caused by pro-
tozoa of genus Leishmania. More than 20 species are found
worldwide causing human leishmaniasis. The vector for the
disease is phlebotomine (sand flies) and is manifested in three
major clinical forms: cutaneous (CL), mucocutaneous and
visceral leishmaniasis (VL). VL, the most severe form of
leishmaniasis, is also known as kala-azar in India. The symp-
toms ofVL include fever, hepatosplenomegaly and anaemia that
may lead to death. The pathogen is endemic in 88 countries.
Nearly 12 million people were infected and 2 million new cases
occur every year. An estimated 350 million people are living
at risk of contracting leishmaniasis. One of the major threats
to control VL is its association with HIV infection (Trouiller and
Olliaro, 1999; Alvar et al., 2012; WHO, 2012). Pentavalent anti-
monials remain the first-line, while polyene antifungal,
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amphotericin B, as a second-line treatment is currently used
in many countries. AmBisome (liposomal amphotericin B) and
miltefosine were also included in the treatment of VL (Reddy
et al., 2007; Sindermann et al., 2004; Thakur et al., 1999).
However, the use of these existing drugs is limited due to several
complications, such as high cost, toxicity, parenteral admin-
istration, emergence and spread of drug resistance, and relapses
in HIV-leishmania co-infected patients.Therefore, there is still
a need for new efficacious and safe agents against
leishmaniasis.
Hydrazides have emerged as biologically and pharmaco-
logical promising agents, with antileishmanial (Sagsehetti et al.,
2014), antitubercular (Ramamurthy and Bhatt, 1989), anticon-
vulsant (Kaushik et al., 2010), antibacterial (Sridhar et al., 2002),
antifungal (Mallikarjuna et al., 2009), anti-HIV (Vicini et al., 2009),
antioxidant (Gurkok et al., 2009), and many more. Hence it was
worth to synthesize these compounds.
2. Materials and methods
2.1. Chemistry
All the chemicals were supplied by Merck (Germany) and S. D.
Fine Chemicals (India). Melting points were determined by open
tube capillary method and were uncorrected. Purity of the com-
pounds was checked by elemental analysis and the progress
of reactions was monitored throughout by thin layer chroma-
tography (TLC) plates (silica gel G) using mobile phase,
hexane:ethylacetate (1:1), and the spots were identified by iodine
vapours or UV light. IR spectra were recorded on a Schimadzu
8201 PC, FT-IR spectrometer (KBr pellets). 1H NMR spectra were
recorded on a Bruker AC 300 MHz spectrometer using TMS as
internal standard in DMSO d6. Mass spectra were recorded on
a Bruker Esquire LCMS using ESI and elemental analyses were
performed on Perkin-Elmer 2400 Elemental Analyzer.
2.2. Synthesis of ethyl(substitutedphenoxy)acetate
analogues (3a-d)
Amixture of equimolar amounts of the substituted phenol and
ethyl chloroacetate was taken in a round bottom flask and sus-
pended in 50–60 ml acetone, and anhydrous potassium
carbonate (1–2 g) was added in the mixture. The mixture was
refluxed for 24 h on the sand bath with vigorous stirring. The
completion of the reaction was monitored byTLC using mobile
phase hexane:ethylacetate (1:1). Initially, the colour of reac-
tion mixture was colourless in case of phenol, while in other
substituted phenols the colour was light yellow and the reac-
tion proceeded until the reactionmixture became dark in colour.
The reaction mixture, when cooled, was filtered under vacuum
to remove solid potassium carbonate and the filtrate thus ob-
tained was evaporated under vacuum. The residue thus
obtained was dissolved into ethylacetate (10–15 ml) and washed
with water twice. Ethylacetate layer was separated and dried
over anhydrous sodium sulphate. The solvent was evapo-
rated under vacuum and the products thus obtained were used
for the next step.
2.3. Synthesis of 2-(substitutedphenoxy) acetohydrazide
analogues (4a-d)
A solution of ethyl (substitutedphenoxy)acetate (0.01 mol)
(3a-d) and hydrazine hydrate (0.02 mol) was taken in a
round bottom flask and suspended in 50–60 ml ethanol.
The mixture was refluxed for 5–6 h on a sand bath with
vigorous stirring. The reaction was monitored throughout
by TLC. The reaction was continued until the ethyl
(substitutedphenoxy)acetate was consumed completely.
The reaction mixture was poured in crushed ice filtered
under vacuum and washed with water to remove solid
2-(substitutedphenoxy)acetohydrazide analogues (4a-d).
2.4. Synthesis of 4-(substitutedphenoxy) benzaldehyde
analogues (7a-c)
A solution of substituted p-fluorobenzaldehyde (0.01 mol) and
substituted phenol/morpholine (0.012mol) was taken in a round
bottom flask and suspended in 50–60 ml DMSO and anhy-
drous potassium carbonate. The mixture was refluxed for 14–
18 hrs on a sand bath with vigorous stirring.The reaction was
monitored throughout by TLC. Initially, the reaction mixture
was colourless in case of phenol, while in other phenols it was
light yellow and the reaction became dark in colour as it pro-
ceeded and reached to completion. The reaction mixture was
cooled, added water and ethylacetate in a separating funnel,
and the ethylacetate layer was separated and evaporated under
rotatory vacuum evaporator. The solid thus obtained was
washed with ethanol, dried and used for the next step.
2.5. Synthesis of 2-(substitutedphenoxy)-N-
[(aryl)methylidene]-acetohydrazide analogues (8a-n)
A solution of p-fluorobenzaldehyde (5)/substituted
4-(substitutedphenoxy)benzaldehyde analogues (7a-c) (1 mmol)
and 2-(substitutedphenoxy)acetohydrazide analogues (4a-d)
(1 mmol) was taken in a round bottom flask and suspended
in 50–60 ml ethanol and TEA (1.5 mol). The mixture was re-
fluxed for 10–14 h on sand bath with vigorous stirring. The
reaction was monitored throughout by TLC. The reaction
mixture was poured into the cold water and the product was
extracted by ethylacetate using a separating funnel. The
ethylacetate layer was then separated and evaporated under
rotator vacuum evaporator.The solid thus obtained was washed
and crystallized with ethanol.
2.5.1. 2-(2-Chlorophenoxy)-N′-{[4-(2,4-dichlorophenoxy)
phenyl] methylidene}acetohydrazide (8a)
Yield 70%, mp. 148–150 °C, Rf 0.63 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3223.16 (NH), 1682.95 (C=O), 1573.97 (C=N),
1097.53 (—O—), 741.65 (C—Cl); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 4.94 (s, 2H, CH2), 6.72–7.74 (m, 11H,ArH), 7.99 (s, 1H, CH=N),
11.34 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6,
75 MHz) δ ppm: 154.83, 146.83, 143.31, 130.74, 129.94, 129.63,
129.40, 126.55, 124.97, 123.40, 121.88, 117.92, 114.20, 91.81; EI-
MS (m/z) 449.75 (M+), 451.41 (M++2), 453.81 (M++4). Cal/Ana: [C
(56.09) 56.05 H (3.36) 3.38 N (6.23) 6.24].
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2.5.2. 2-(2-Chlorophenoxy)-N′-[(4-phenoxyphenyl)
methylidene] acetohydrazide (8b)
Yield 69%, mp. 135–137 °C, Rf 0.73 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3186.51 (NH), 1680.05 (C=O), 1487.17 (C=N),
1164.08 (—O—), 743.58 (C—Cl); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 5.09 (s, 2H, CH2), 6.69–7.79 (m, 13H,ArH), 8.17 (s, 1H, CH=N),
11.04 (s, 1H, CONH2; D2O exchangeable); 13C NMR (DMSO d6,
75 MHz) δ ppm: 68.61, 115.72, 117.21, 117.90, 121.92, 122.56,
122.63, 126.91, 127.90, 128.51, 128.93, 129.92, 143.14, 154.71, 157.01,
159.33, 168.16; EI-MS (m/z) 381.41 (M+), 383.44 (M++2). Cal/Ana:
[C (66.23) 66.19 H (4.50) 4.53 N (7.36) 7.32].
2.5.3. 2-(2-Chlorophenoxy)-N′-{[4-(morpholin-4-yl)phenyl]
methylidene} acetohydrazide (8c)
Yield 74%, mp. 128–130 °C, Rf 0.76 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3181.69 (NH), 1682.95 (C=O), 1493.92 (C=N),
1121.64 (—O—, morpholine), 747.44 (C—Cl); 1H NMR (DMSO d6,
300 MHz) δ ppm: 2.40–2.45 (t, 4H, morpholine), 3.71–3.72 (t, 4H,
morpholine), 4.84 (s, 2H, CH2), 6.70–7.36 (m, 8H, ArH), 8.27 (s,
1H, CH=N), 11.41 (s, 1H, CONH; D2O exchangeable); 13C NMR
(DMSO d6, 75 MHz) δ ppm: 46.31, 66.11, 68.60, 114.41, 115.72,
122.51, 122.68, 123.33, 127.94, 129.92, 130.09, 143.01, 151.92, 154.71,
168.66; EI-MS (m/z) 373.44 (M+), 375.49 (M++2). Cal/Ana: [C (61.04)
61.01 H (5.39) 5.43 N (11.24) 11.19].
2.5.4. 2-(2-Chlorophenoxy)-N′-[(4-fluorophenyl)methylidene]
acetohydrazide (8d)
Yield 56%, mp. 122–124 °C, Rf 0.62 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3200.02 (NH), 1680.12 (C=O), 1457.16 (C=N),
1196.02 (—O—), 687.12 (C—F); 1H NMR (DMSO d6) δ ppm: 4.83
(s, 2H, CH2), 6.81–7.46 (m, 8H, ArH), 7.99 (s, 1H, CH=N), 11.02
(s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6, 75 MHz)
δ ppm: 68.51, 115.63, 115.71, 122.56, 122.61, 127.91, 129.41, 129.92,
130.82, 143.01, 154.72, 165.22, 168.01; EI-MS (m/z) 306.24 (M+),
308.37 (M++2). Cal/Ana: [C (58.74) 58.69 H (3.94) 3.89 N (9.13) 9.09].
2.5.5. N′-{[4-(2,4-Dichlorophenoxy)phenyl]methylidene}-2-
(2-methyl-phenoxy)acetohydrazide (8e)
Yield 84%, mp. 150–152 °C, Rf 0.54 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3220.27 (NH), 1678.13 (C=O), 1574.93 (C=N),
1099.46 (—O—), 714.65 (C—Cl); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 2.23 (s, 3H, CH3), 4.64 (s, 2H, CH2), 6.82–7.79 (m, 11H, ArH),
7.98 (s, 1H, CH=N), 11.45 (s, 1H, CONH; D2O exchangeable); 13C
NMR (DMSO d6, 75 MHz) δ ppm: 14.41, 69.42, 114.21, 117.62,
120.33, 121.01, 124.51, 126.72, 126.81, 126.97, 127.21, 128.83, 128.96,
130.11, 131.01, 143.01, 150.11, 158.77, 159.31, 168.99; EI-MS (m/z)
429.45 (M+), 431.45 (M++2) 433.44 (M++4). Cal/Ana: [C (61.55) 61.51
H (4.23) 4.19 N (6.53) 6.49].
2.5.6. 2-(2-Methylphenoxy)-N′-[(4-phenoxyphenyl)
methylidene] acetohydrazide (8f)
Yield 82%, mp. 145–147 °C, Rf 0.63 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3237.63 (NH), 1680.05 (C=O), 1497.78 (C=N),
1192.05 (—O—); 1H NMR (DMSO d6, 300 MHz) δ ppm: 2.23 (s, 3H,
CH3), 5.12 (s, 2H, CH2), 6.79–7.97 (m, 13H,ArH), 8.27 (s, 1H, CH=N),
11.44 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6,
75 MHz) δ ppm: 14.44, 69.92, 114.21, 117.51, 118.63, 121.01, 121.92,
124.51, 126.18, 126.99, 128.55, 129.91, 130.11, 143.12, 157.01, 158.71,
159.93, 168.66; EI-MS (m/z) 460.11 (M+), 461.09 (M++1). Cal/Ana:
[C (73.32) 73.29 H (5.59) 5.55 N (7.77) 7.72].
2.5.7. 2-(2-Methylphenoxy)-N′-{[4-(morpholin-4-yl)phenyl]
methylidene} acetohydrazide (8g)
Yield 73%, mp. 136–138 °C, Rf 0.65 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3195.19 (NH), 1670.41 (C=O), 1553.71 (C=N),
1190.12 (—O—), 1123.57 (—O—,morpholine ring); 1H NMR (DMSO
d6, 300 MHz) δ ppm: 2.31 (s, 3H, CH3), 2.96–2.98 (t, 4H,
morpholine), 3.62–3.64 (t, 4H,morpholine), 4.82 (s, 2H, CH2), 6.69–
7.62 (m, 8H, ArH), 7.92 (s, 1H, CH=N), 11.02 (s, 1H, CONH; D2O
exchangeable); 13C NMR (DMSO d6, 75 MHz) δ ppm: 14.45, 46.33,
66.42, 69.62, 114.21, 114.92, 121.01, 123.33, 124.55, 126.81, 130.11,
130.96, 143.09, 151.99, 158.72, 168.72; EI-MS (m/z) 353.11 (M+),




Yield 65%, mp. 164–166 °C, Rf 0.72 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3185.12 (NH), 1674.46 (C=O), 1453.71 (C=N),
1194.12 (—O—), 697 (C—F); 1H NMR (DMSO d6, 300 MHz) δ ppm:
2.33 (s, 3H, CH3), 4.92 (s, 2H, CH2), 6.62–7.32 (m, 8H, ArH), 7.89
(s, 1H, CH=N), 10.97 (s, 1H, CONH; D2O exchangeable); 13C NMR
(DMSO d6, 75 MHz) δ ppm: 14.46, 69.42, 114.21, 115.56, 121.22,
125.09, 126.81, 129.92, 130.31, 131.11, 143.11, 158.71, 165.22, 168.99;
EI-MS (m/z) 286.35 (M+), 287.49 (M++1). Cal/Ana: [C (67.12) 67.07
H (5.28) 5.29 N (9.78) 9.76].
2.5.9. 2-(2,4-Dichlorophenoxy)-N′-{[4-(2,4-dichlorophenoxy)
phenyl] methylidene}acetohydrazide (8i)
Yield 62%, mp. 138–140 °C, Rf 0.68 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3220.27 (NH), 1678.13 (C=O), 1474.63 (C=N),
1099.46 (—O—), 714.65 (C—Cl); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 4.54 (s, 2H, CH2), 6.72–7.71 (m, 10H,ArH), 7.97 (s, 1H, CH=N),
11.15 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6) δ
ppm: 66.18, 115.57, 117.76, 117.91, 123.40, 124.97, 126.55, 128.29,
129.41, 129.63, 129.94, 130.74, 143.68, 150.53, 153.29, 158.09, 168.63;
EI-MS: (m/z) 481.51 (M+), 483.50 (M++2), 485.49 (M++4). Cal/Ana:
[C (52.10) 52.05 H (2.91) 2.89 N (5.79) 5.77].
2.5.10. 2-(2,4-Dichlorophenoxy)-N′-[(4-phenoxyphenyl)
methylidene] acetohydrazide (8j)
Yield 72%, mp. 144–146 °C, Rf 0.69 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3190.37 (NH), 1680.05 (C=O), 1586.50 (C=N),
1165.04 (—O—), 689.57 (C—Cl); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 5.28 (s, 2H, CH2), 7.02–7.73 (m, 12H,ArH), 7.99 (s, 1H, CH=N),
11.62 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6,
75 MHz) δ ppm: 68.66, 117.71, 118.11, 118.90, 121.01, 124.91,
126.91, 128.01, 128.91, 129.10, 129.94, 131.41, 143.33, 152.82, 157.01,
159.91, 168.62; EI-MS (m/z) 415.26 (M+), 417.43 (M++2). Cal/Ana:
[C (60.74) 60.71 H (3.88) 3.89 N (6.75) 6.73].
2.5.11. 2-(2,4-Dichlorophenoxy)-N′-{[4-(morpholin-4-yl)
phenyl] methylidene}acetohydrazide (8k)
Yield 71%, mp. 130–132 °C, Rf 0.66 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3182.65 (NH), 1681.02 (C=O), 1528.65 (C=N),
1185.30 (—O—, morpholine), 724.29 (C—Cl); 1H NMR (DMSO d6,
300 MHz) δ ppm: 4.84 (s, 2H, CH2), 2.40–2.45 (t, 4H, morpholine),
3.71–3.72 (t, 4H, morpholine), 6.70–7.36 (m, 8H, ArH), 8.27 (s, 1H,
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CH=N), 11.41 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO
d6, 75 MHz) δ ppm: 46.32, 66.01, 68.16, 114.41, 117.11, 123.01,
124.10, 128.11, 128.94, 130.19, 131.02, 143.12, 151.92, 152.81, 168.72;
EI-MS (m/z) 408.54 (M+), 409.55 (M++2), 411.49 (M++4). Cal/Ana:
[C (55.89) 55.85 H (4.69) 4.63 N (10.29) 10.25].
2.5.12. 2-(2,4-Dichlorophenoxy)-N′-[(4-fluorophenyl)
methylidene] acetohydrazide (8l)
Yield 58%, mp. 172–174 °C, Rf 0.77 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3192.61 (NH), 1679.02 (C=O), 1483.21 (C=N),
1198.30 (—O—), 687.29 (C—F); 1H NMR (DMSO d6, 300 MHz) δ
ppm: 4.91 (s, 2H, CH2), 6.72–7.31 (m, 7H,ArH), 7.87 (s, 1H, CH=N),
10.42 (s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6,
75 MHz) δ ppm: 68.12, 115.56, 117.11, 124.01, 128.11, 128.91,
129.44, 130.18, 131.41, 143.12, 152.81, 168.16; EI-MS (m/z) 340.11
(M+), 341.23 (M++1), 342.54 (M++2). Cal/Ana: [C (52.81) 52.85 H (3.25)
3.23 N (8.21) 8.25].
2.5.13. 2-Phenoxy-N′-[(4-phenoxyphenyl)methylidene]
acetohydrazide (8m)
Yield 60%, mp. 140–142 °C, Rf 0.78 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3083.31 (NH), 1680.05 (C=O), 1562.39 (C=N),
1192.05 (—O—); 1H NMR (DMSO d6, 300 MHz) δ ppm: 5.04 (s, 2H,
CH2), 6.76–7.91 (m, 13H, ArH), 8.02 (s, 1H, CH=N), 11.14 (s, 1H,
CONH; D2O exchangeable); 13C NMR (DMSO d6, 75 MHz) δ ppm:
69.01, 114.31, 117.51, 117.61, 121.09, 121.91, 126.92, 128.50, 128.91,
129.79, 143.11, 157.11, 159.32, 168.19; EI-MS (m/z) 346.54 (M+),
347.49 (M++1), 348.49 (M++2). Cal/Ana: [C (72.82) 72.78 H (5.24)
5.23 N (8.09) 8.05].
2.5.14. N′-[(4-Fluorophenyl)methylidene]-2-
phenoxyacetohydrazide (8n)
Yield 62%, mp. 168–170 °C, Rf 0.74 [hexane: ethylacetate (1:1)],
IR (KBr) cm−1: 3231.63 (NH), 1679.05 (C=O), 1493.78 (C=N),
1191.05 (—O—), 688 (C—F); 1H NMR (DMSO d6, 300 MHz) δ ppm:
4.98 (s, 2H, CH2), 6.71–7.27 (m, 8H,ArH), 7.96 (s, 1H, CH=N), 11.12
(s, 1H, CONH; D2O exchangeable); 13C NMR (DMSO d6, 75 MHz)
δ ppm: 69.11, 114.31, 115.63, 121.11, 129.42, 129.89, 130.83, 143.12,
168.66; EI-MS (m/z) 272.11 (M+), 273.23 (M++1). Cal/Ana: [C (66.17)
66.11 H (4.81) 4.83 N (10.29) 10.25].
2.6. In vitro antileishmanial activity
Promastigotes of Indian Leishmania donovani strain MHOM/IN/
83/AG83 was obtained from the culture bank of Rajendra
Memorial Research Institute of Medical Sciences (ICMR), Patna,
India. The cryo-cells were revived and grown in RPMI 1640
medium (Sigma-Aldrich) supplemented with 10% foetal calf
serum (FCS: Sigma-Aldrich) in BOD incubator at 25 °C.
Specimens were dissolved in dimethyl sulphoxide (DMSO)
and further dilutions were made with RPMI 1640 medium
(Navarro et al., 2010; Vitale et al., 1989). The concentrations of
500, 250, 125, 62.5, 31.25, 15.6, 7.8, 3.9, and 1.9 (μg/ml) were pre-
pared from the stock solution of 10 mg/ml in DMSO solution
by serial dilution methods. Promastigotes were adapted for
growth at 25 °C in RPMI 1640 (Sigma-Aldrich) and supple-
mented with 20% heat inactivated foetal bovine serum (Miguel
et al., 2007). Logarithmic phase cultures were used for experi-
mental purposes, and the in vitro susceptibility assay was
performed in sterilized 96-well culture micro titre plates (Nunc)
(Rolón et al., 2006). A dose of 2.5 × 106 parasites was added to
each well to a final volume of 200 ml, together with the drug
concentration. Growth of promastigotes was monitored after
48 h by counting the number of motile promastigotes micro-
scopically in a Neubauer chambers.The log dose and response
were used to calculate the 50% inhibitory concentrations (IC50)
of compounds. IC50 was calculated by linear regression analy-
sis with 95% confidence limits. Tests were performed at least
in triplicate on three different days in order to verify the results
and amphotericin B was used as positive control.
2.7. Cytotoxicity
The active compounds were tested for cytotoxicity (IC50) inVERO



















































Fig. 1 – Protocol for the synthesis of acetohydrazide analogues (8a-n).
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Table 1 – Antileishmanial activity and cytotoxicity evaluation of the newer acetohydrazide analogues (8a-n).
S. no. Compound Structure IC50 (μM) IC50 (μM)
L. donovania Vero
1 8a 280.05 ± 34.71 ND
2 8b 59.29 ± 25.28 164.11
3 8c 242.06 ± 52.67 ND
4 8d 242.92 ± 37.88 ND
5 8e 183 ± 29.14 >145.59
6 8f 194.03 ± 73.58 >173.42
7 8g 171.44 ± 72.52 ND
8 8h 252.39 ± 32.34 ND
9 8i 110.23 ± 32.74 ND
10 8j 144.60 ± 46.33 150.51
11 8k 48.10 ± 25.86 >153.08
12 8l 270 ± 37.93 ND
13 8m 208.55 ± 27.60 ND
14 8n 466.89 ± 47.49 ND
15 Amphotericin B – 0.69 ± 0.13 ND
a Promastigotes of Leishmania donovani; ND: not determined.
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viability was assessed on the basis of cellular conversion of
MTT into a formazan product using the Promega Cell Titer 96
Non-Radioactive Cell Proliferation method (Heifets et al., 1989).
3. Results and discussion
3.1. Chemistry
In the first step equimolar mixture of substituted phenol
and ethyl chloroacetate was suspended in acetone anhy-
drous potassium carbonate and refluxed for 24 h to
ethyl(substitutedphenoxy)acetate analogues (3a-d), which was
further treated with hydrazine hydrate for 5–6 h in ethanol to
obtain 2-(substitutedphenoxy)acetohydrazide analogues (4a-
d). On the other hand 4-(substitutedphenoxy)benzaldehyde
analogues (7a-c) were synthesized from 4-fluorobenzaldehyde
and substituted phenol and morpholine in DMSO and anhy-
drous potassium carbonate by refluxing for 14–18 h.We have
used different reaction conditions for the synthesis of
4-(substitutedphenoxy)benzaldehyde analogues (7a-c) from the
earlier reported method (Joshi et al., 2010; Tripathi and Kumar,
2013). In the final step the aromatic aldehydes (5 and 7a-c)
and 2-(substitutedphenoxy)acetohydrazide analogues (4a-d)
were refluxed for 10–14 h in ethanol and triethylamine (TEA)
to obtain the final product 2-(substitutedphenoxy)-N-
[(aryl)methylidene]acetohydrazide analogues (8a-n).The reaction
was monitored throughout byTLC using chloroform-methanol
(9:1) and hexane:ethylacetate (1:1) as mobile phase. The spots
were located under iodine vapour/UV light. The reaction se-
quence is shown in Fig. 1. The synthesized compounds were
characterized by spectral analysis and all the compounds were
in full harmony with the proposed structures. In general the
IR spectra afforded absorption at 3237–3181 cm−1 due to N—H
stretching, 1682–1670 cm−1 band due to C=O, 1573–1453 cm−1
band due to C=N and 1056–1198 cm−1 due to ether stretch-
ing. In 1H NMR the signals of the respective protons of the
synthesized title compounds were verified on the basis of their
chemical shifts and multiplicities in DMSO d6. The spectra
showed a singlet at δ 2.23–2.33 ppm corresponding to CH3
(Ar—CH3); a multiplet at δ 2.40–3.72 ppm corresponding to
morpholine protons; a singlet at δ 4.54–5.28 ppm to CH2 (methy-
lene bridge); a singlet at δ 6.69–7.97 ppm corresponding to
aromatic protons; a singlet at δ 7.79–8.27 ppm corresponding
to imine proton (CH=N); and a multiplet at δ 10.42–11.62 ppm
(D2O exchangeable) corresponding to amide (CONH).
3.2. Antileishmanial activity and cytotoxicity
Compounds were screened for in vitro antileishmanial activ-
ity against promastigotes of Leishmania donovani between 48.11
and 466.88 μM.The most active compounds of the series was
8k (IC50 48.11 ± 25.86 μM) followed by 8b (IC50 59.29 ± 25.28 μM)
while rest of the compounds showed moderate to low activ-
ity with IC50 between 110.23 ± 32.74 and 466.88 ± 47.49 μM
(Table 1). The antileishmanial activity was carried out in
μg/ml and later converted in μM. The SAR explored from the
data showed that the terminal aryl group with 4-(4-
phenyl)morpholine as in compound 8k showed maximum
antileishmanial activity and the activity decreased with
4-phenoxybenzene, 4-fluorophenyl and 2,4-dichloro-1-(4-
phenoxy)benzene.The O-aryl group (acetohydrazide) with 2,4-
dichlorophenyl (as in compound 8k) showedmaximum activity
followed by 2-chlorophenyl, 2-methylphenyl and unsubstituted
phenyl respectively.Two compounds (8b and 8k) showed prom-
ising activity against the promastigotes of L. donovani and SAR
confirmed that the compound 8k could be considered as lead
for further optimization. Further 5 compounds were screened
for cytotoxic studies. The results of cytotoxic studies showed
that the active compounds (8b and 8k) were found to be non-
toxic with IC50 of 164.11 and >153.08 μM respectively (Table 1).
4. Conclusion
All the compounds were synthesized in satisfactory yield. All
the compounds were characterized by IR, NMR and mass spec-
tral data. The antileishmanial activity was carried out for all
the compounds against the promastigotes of Leishmania
donovani. Standard protocol was followed for antileishmanial
activity. Some of the compounds showed promising
antileishmanial activity. The compound 8k showed the
maximum antileishmanial activity with could be considered
as lead for antileishmanial activity. The cytotoxic studies also
showed that the compound 8k was found to be non-toxic.The
detailed molecular modelling and chemical modifications
studies are in progress in our laboratory.
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